Wilson Sonsini Goodrich & Rosati advised Versant Ventures and OrbiMed on the transaction. Helicore Biopharma, a biopharmaceutical company focused on the discovery and development of first-in-class...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Versant Ventures on this transaction. ierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Versant Ventures and New Enterprise Associates on the deal. Nexo Therapeutics (Nexo) announced it has emerged from stealth with $60 million...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Versant Ventures on the deal. Versant Ventures announced the debut of Vector BioPharma, a biopharmaceutical company developing a precision gene delivery platform that...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Versant Ventures on the deal. VISCHER advised Cimeo Therapeutics. Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised New Enterprise Associates (NEA) and Versant Ventures on the deal. 858 Therapeutics announced the completion of a $60 million Series...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Versant Ventures and NEA on the deal. Stablix Therapeutics announced a $63 million Series A financing. The funding round was...
You must be a Standard 1 Year member to access this content.
